Core Viewpoint - Eli Lilly announced that a limited number of basic Medicare drug plans may not adhere to the $50 per month cap on out-of-pocket costs for its weight-loss drugs, as per the Medicare agency's weight-loss drug coverage model [1] Summary by Category - **Company Impact** - Eli Lilly's weight-loss drugs may face variability in out-of-pocket costs for patients depending on the Medicare drug plans they are enrolled in [1] - **Industry Implications** - The announcement highlights potential inconsistencies in Medicare coverage for weight-loss drugs, which could affect patient access and overall market dynamics for pharmaceutical companies in this sector [1]